Creating Multi-specific ADCs to Overcome Tumour Heterogeneity & Improve Specificity
1:30 pm - Monday 8th March 2027
- Delivering broader tumour targeting and more robust anti-tumour activity with multi-specific ADCs by simultaneously engaging multiple antigens
- Addressing tumour heterogeneity with multi TAA targeting may enhance response rates and durability only when optimal antigen pairings are selected
- Reducing the risk of on-target toxicity and antigen escape that arises from single-antigen loss, provided that antigen pairings minimise rather than exacerbate normal tissue liabilities
